| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $20,777,886 | 7 | 44 |
Sells | $45,693 | 9 | 56 |
| GILEAD SCIENCES, INC. | 10 percent owner | 1 | $20.1M | 0 | $0 | $20.1M |
| Schornstein Alexander | 10 percent owner | 5 | $629,425 | 0 | $0 | $629,425 |
| Houghton Michael | director | 1 | $49,998 | 0 | $0 | $49,998 |
| Bjorkquist Jeanette M | Principal Accounting Officer | 0 | $0 | 1 | $1,773 | $-1,773 |
| McHutchison John G | director | 0 | $0 | 1 | $7,455 | $-7,455 |
| White Nicole S | Chief Manufacturing Officer | 0 | $0 | 4 | $16,089 | $-16,089 |
| Okazaki Jason A | CEO and President | 0 | $0 | 3 | $20,376 | $-20,376 |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $20.78M and sold $45,693 worth of Assembly Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $10.79M and sold $135,811 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $20.1M. Schornstein Alexander (10 percent owner) — $629,425. Houghton Michael (director) — $49,998.
The last purchase of 3,202 shares for transaction amount of $49,998 was made by Houghton Michael (director) on 2024‑12‑30.
| 2025-03-31 | Sale | McHutchison John G | director | 757 0.0104% | $9.85 | $7,455 | +30.96% | |
| 2025-03-31 | Sale | Okazaki Jason A | CEO and President | 355 0.0049% | $9.85 | $3,496 | +30.96% | |
| 2025-03-31 | Sale | White Nicole S | Chief Manufacturing Officer | 197 0.0027% | $9.85 | $1,940 | +30.96% | |
| 2025-03-31 | Sale | Bjorkquist Jeanette M | Principal Accounting Officer | 180 0.0025% | $9.85 | $1,773 | +30.96% | |
| 2024-12-30 | Houghton Michael | director | 3,202 0.0519% | $15.61 | $49,998 | -20.06% | ||
| 2024-12-19 | GILEAD SCIENCES, INC. | 10 percent owner | 940,499 20.3736% | $21.37 | $20.1M | -17.30% | ||
| 2024-11-25 | Schornstein Alexander | 10 percent owner | 7,976 0.126% | $14.91 | $118,890 | -8.78% | ||
| 2024-11-22 | Schornstein Alexander | 10 percent owner | 17,024 0.2729% | $14.87 | $253,104 | -9.87% | ||
| 2024-11-18 | Sale | White Nicole S | Chief Manufacturing Officer | 40 0.0006% | $16.29 | $652 | -13.70% | |
| 2024-10-08 | Schornstein Alexander | 10 percent owner | 10,000 0.1478% | $14.58 | $145,800 | +0.07% | ||
| 2024-10-03 | Sale | Okazaki Jason A | CEO and President | 197 0.003% | $14.81 | $2,918 | -1.74% | |
| 2024-10-03 | Sale | White Nicole S | Chief Manufacturing Officer | 157 0.0024% | $14.81 | $2,325 | -1.74% | |
| 2024-08-02 | Sale | Okazaki Jason A | CEO and President | 981 0.0158% | $14.23 | $13,962 | +3.01% | |
| 2024-08-02 | Sale | White Nicole S | Chief Manufacturing Officer | 785 0.0127% | $14.23 | $11,173 | +3.01% | |
| 2024-07-05 | Schornstein Alexander | 10 percent owner | 4,438 0.063% | $12.52 | $55,564 | +11.43% | ||
| 2024-07-03 | Schornstein Alexander | 10 percent owner | 4,562 0.0636% | $12.29 | $56,067 | +21.15% | ||
| 2024-06-17 | GILEAD SCIENCES, INC. | 10 percent owner | 179,500 0.0002% | $0.00 | $180 | -2.90% | ||
| 2024-05-23 | Sale | McHutchison John G | director | 2,117 0.0389% | $14.93 | $31,615 | -0.07% | |
| 2024-05-23 | Sale | Okazaki Jason A | CEO and President | 549 0.0101% | $14.93 | $8,199 | -0.07% | |
| 2024-05-23 | Sale | White Nicole S | Chief Manufacturing Officer | 172 0.0032% | $14.93 | $2,569 | -0.07% |
| GILEAD SCIENCES, INC. | 10 percent owner | 2209471 28.9291% | $37.87M | 2 | 0 | |
| Schornstein Alexander | 10 percent owner | 728113 9.5333% | $12.48M | 9 | 0 | +64% |
| McHutchison John G | director | 18347 0.2402% | $314,467.58 | 0 | 9 | |
| Okazaki Jason A | CEO and President | 14757 0.1932% | $252,934.98 | 0 | 14 | |
| White Nicole S | Chief Manufacturing Officer | 11674 0.1529% | $200,092.36 | 0 | 9 | |
| Bjorkquist Jeanette M | Principal Accounting Officer | 4617 0.0605% | $79,135.38 | 0 | 6 | |
| Houghton Michael | director | 3202 0.0419% | $54,882.28 | 1 | 0 | |
| Small Derek A | CEO and President | 669291 8.7632% | $11.47M | 3 | 0 | <0.0001% |
| Lopatin Uri A | Chief Med. Off., VP Res. Dev. | 613611 8.0341% | $10.52M | 0 | 2 | |
| Delaney William E IV | Chief Scientific Officer | 150853 1.9751% | $2.59M | 0 | 8 | |
| Colonno Richard James | EVP & CSO, Virology Ops | 137009 1.7939% | $2.35M | 0 | 2 | |
| Samar Michael P. | Chief Financial Officer | 77228 1.0112% | $1.32M | 0 | 2 | |
| ELLISON RUSSELL H | Chief Executive Officer | 58000 0.7594% | $994,120.00 | 6 | 0 | +59.75% |
| BARRETT DAVID JONATHAN | Chief Financial Officer | 46980 0.6151% | $805,237.20 | 3 | 0 | +86.04% |
| Stamm Luisa M | Chief Medical Officer | 40315 0.5279% | $690,999.10 | 0 | 2 | |
| Papkoff Jacqueline Sybil | SVP-CSO Microbiome | 37364 0.4892% | $640,418.96 | 0 | 3 | |
| RINGO WILLIAM R | director | 19465 0.2549% | $333,630.10 | 0 | 11 |
$5,558,275 | 76 | -5.88% | $119.25M | |
$11,468,215 | 44 | 17.78% | $163.81M | |
$48,218,096 | 42 | 0.89% | $120.52M | |
$16,245,616 | 40 | 123.58% | $140.18M | |
$140,938,207 | 36 | 14.75% | $122.55M | |
$63,049,419 | 31 | 2.87% | $126.16M | |
$294,424,120 | 20 | 1.33% | $138.71M | |
Assembly Biosciences, Inc. (ASMB) | $1,239,833 | 16 | 53.23% | $130.91M |
$448,999,793 | 15 | -19.99% | $129.14M | |
$178,593,887 | 15 | -14.86% | $132.49M | |
$10,143,329 | 12 | 11.84% | $154.55M | |
$9,999,920 | 10 | -40.03% | $117.01M | |
$22,090,972 | 7 | -3.49% | $164.38M | |
$299,343 | 6 | -44.75% | $119.05M | |
$63,981 | 5 | -11.55% | $126.38M | |
$32,289,200 | 3 | -5.46% | $145.99M | |
$9,999,990 | 2 | 25.53% | $140.76M | |
$20,020,000 | 1 | -75.24% | $125.77M | |
$300,016 | 1 | -50.33% | $141.86M |
| Increased Positions | 17 | +44.74% | 246,092 | +7.72% |
| Decreased Positions | 14 | -36.84% | 256,181 | -8.04% |
| New Positions | 6 | New | 43,300 | New |
| Sold Out Positions | 4 | Sold Out | 73,019 | Sold Out |
| Total Postitions | 41 | +7.89% | 3M | -0.32% |
| Gilead Sciences, Inc. | $31,330.00 | 27.62% | 2.21M | +2M | New | 2024-12-31 |
| Vanguard Group Inc | $2,842.00 | 2.51% | 200,458 | 0 | 0% | 2024-12-31 |
| Armistice Capital, Llc | $2,383.00 | 2.1% | 168,074 | -185,926 | -52.52% | 2024-12-31 |
| Renaissance Technologies Llc | $1,343.00 | 1.18% | 94,711 | +29,087 | +44.32% | 2024-12-31 |
| Blackrock, Inc. | $1,120.00 | 0.99% | 78,988 | -2,541 | -3.12% | 2025-03-31 |
| B Group, Inc. | $718.00 | 0.63% | 50,651 | +50,651 | New | 2024-12-31 |
| Geode Capital Management, Llc | $661.00 | 0.58% | 46,635 | -399 | -0.85% | 2024-12-31 |
| Monimus Capital Management, Lp | $597.00 | 0.53% | 42,067 | +42,067 | New | 2024-12-31 |
| Northern Trust Corp | $406.00 | 0.36% | 28,649 | -1,175 | -3.94% | 2024-12-31 |
| Federated Hermes, Inc. | $360.00 | 0.32% | 25,394 | 0 | 0% | 2024-12-31 |